Financial News

Everest Medicines Starts China Trial of Triple-Negative Breast Cancer ADC

Everest Medicines has dosed the first patient in a registrational China Phase IIb trial of Trodelvy TM to treat metastatic triple-negative breast cancer. Trodelvy (sacituzumab govitecan) is a first-in-class antibody-drug conjugate directed at TROP-2, a membrane antigen that is over-expressed in many common epithelial cancers. Last year, Everest in-licensed Greater China rights to Trodelvy from Immunomedics in an agreement worth up to $835 million. Immunomedics recently released US Phase III data showing significantly improved PFS and OS results for Trodelvy. More details.... Stock Symbols: (HK:1952) (NSDQ: IMMU) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback